{"id":"W4391506607","doi":"10.1016/j.esmoop.2023.102226","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bayer Yakuhin; Sierra Oncology; Eli Lilly Japan; Pfizer Japan; Novartis Pharma; INCLIVA Instituto de Investigación Sanitaria; Ipsen; Teijin Pharma; Japanese Society of Medical Oncology; Otsuka Pharmaceutical; Daiichi Sankyo Europe; Veracyte; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Natera; Daiichi-Sankyo; MacroGenics; AstraZeneca; Genentech; Sysmex Corporation; Astellas Pharma; Eisai; FibroGen; Fondazione Beretta; BeiGene; Mirati Therapeutics; Hellenic Society of Medical Oncology; Pharmacyclics; Exelixis; Kissei; Pfizer; American Association for Cancer Research; Servier; Incyte; JST-Mirai Program; Astellas Foundation for Research on Metabolic Disorders; Gilead Sciences; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Sanofi; Amgen; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; SymBio Pharmaceuticals Limited; American Society of Clinical Oncology; Foundation Medicine; GlaxoSmithKline; Seagen; Relay Therapeutics","keywords":"Medicine; Cancer; Clinical Practice; Intensive care medicine; Internal medicine; Oncology; Family medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01380552,0.001214362,0.001511484,0.004670317,0.001094462,0.002719365,0.002958505,0.005314683,0.01105253],"category_scores_gemma":[0.04991398,0.0006833457,0.003999011,0.00410259,0.00108634,0.002068273,0.003436376,0.005099627,0.009666139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003974578,"about_ca_system_score_gemma":0.01928944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01578033,"about_ca_topic_score_gemma":0.02709851,"domain_scores_codex":[0.9830599,0.007150862,0.004931721,0.0005802465,0.003457684,0.0008195607],"domain_scores_gemma":[0.9599335,0.005264464,0.004081279,0.0009937214,0.02813458,0.001592485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001814694,0.0001455607,0.004112933,0.010189,0.0002759204,0.0008017884,0.001134649,0.0008359238,0.0009813908,0.005023079,0.7581396,0.2181786],"study_design_scores_gemma":[0.000232204,0.000103648,0.00807471,0.02610011,0.000291881,0.00130296,0.0006513665,0.0005484049,0.0004177018,0.004234876,0.9579466,0.00009551732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.008929159,0.2073704,0.07323891,0.3673671,0.03697591,0.01856099,0.04032984,0.002398154,0.2448296],"genre_scores_gemma":[0.06263563,0.2628053,0.341437,0.145157,0.009378137,0.0314653,0.07571726,0.001114923,0.07028957],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.01578033,"threshold_uncertainty_score":0.07301146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1231281084762858,"score_gpt":0.4420520611936647,"score_spread":0.3189239527173789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}